Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large decline in short interest in July. As of July 15th, there was short interest totaling 58,489 shares, a decline of 38.3% from the June 30th total of 94,847 shares. Based on an average daily volume of 825,988 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are sold short.

Oncotelic Therapeutics Stock Up 0.8%

Shares of OTLC traded up $0.00 during mid-day trading on Friday, reaching $0.04. The company’s stock had a trading volume of 5,000 shares, compared to its average volume of 300,521. The business has a fifty day moving average of $0.04 and a 200 day moving average of $0.05. The company has a market cap of $17.69 million, a price-to-earnings ratio of 0.07 and a beta of -0.27. Oncotelic Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.11. The company has a quick ratio of 0.11, a current ratio of 0.11 and a debt-to-equity ratio of 0.01.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.